Active substance
Results for the substance meningococcal group b vaccine recombinant adsorbed
2 results
About this active substance
The group B meningococcal vaccine (recombinant, adsorbed) is used to prevent infections caused by Neisseria meningitidis serogroup B, a bacterium that can cause meningitis and septicemia. The vaccine contains recombinant proteins derived from serogroup B, which stimulate the immune system to produce specific antibodies against this serogroup.
The vaccine is administered intramuscularly, usually in two or three doses, depending on the patient's age and the recommended vaccination schedule. It is particularly indicated for infants, adolescents, and individuals at increased risk of infection.
Common side effects include pain at the injection site, fever, fatigue, and irritability. In rare cases, severe allergic reactions may occur.
The group B meningococcal vaccine (recombinant, adsorbed) is an essential preventive measure for reducing the incidence of meningococcal diseases caused by serogroup B, helping to protect vulnerable populations and prevent severe complications associated with these infections.
The vaccine is administered intramuscularly, usually in two or three doses, depending on the patient's age and the recommended vaccination schedule. It is particularly indicated for infants, adolescents, and individuals at increased risk of infection.
Common side effects include pain at the injection site, fever, fatigue, and irritability. In rare cases, severe allergic reactions may occur.
The group B meningococcal vaccine (recombinant, adsorbed) is an essential preventive measure for reducing the incidence of meningococcal diseases caused by serogroup B, helping to protect vulnerable populations and prevent severe complications associated with these infections.